ICON Announces Clinical Research partnership with DuPage Medical Group
Additional PMG Research site locations enhances ICON’s site and patient engagement capabilities
ICON sponsors industry-wide clinical trials survey to support Transforming Trials initiative
A new survey of pharmaceutical executives and professionals by ICON and Pharma Intelligence, which examines the key challenge of declining research and development (R&D) efficiency.
ICON Reports First Quarter 2018 Results
Q1 2018 Financial Results
ICON and AMAG Pharmaceuticals Honoured as Clinical Research Team of the Year
The award honoured the achievements of the team for executing a Phase III iron deficiency anaemia trial
ICON Receives 2018 CRO Phase IV Leadership Award
ICON recognised for specialised real world evidence and late phase services.
ICON Announces Agreement with Intel
The Intel platform is an edge-to-cloud artificial intelligence (AI) solution that enables remote monitoring and continuous capture of clinical data.
ICON announces launch of Government and Public Health Solutions
ICON GPHS provide full service clinical development and staffing services across multiple agencies in the US Government, NGOs, Academic Institutions and others in the global health space.
ICON Reports Fourth Quarter and Full Year 2017 Results
Quarter 4 net revenue increased 4.6% year on year to $455 million.
ICON appoints Dr. James Cummings as President of ClinicalRM
ClinicalRM is a wholly owned subsidiary of ICON plc, providing full service and functional research solutions to a range of U.S. Federal Health Agencies.
ICON Issues Financial Guidance for Full Year 2018
ICON plc today announced its financial guidance for the year ended December 31, 2018.